News About: Goverment
Appetite suppressing drugs on market boom.
Anti-obesity drugs such as Reductil and Xenical have made a remarkable market success, and other followers including Phendimetrazine and Phentermine preparations are adding more fuel to its flames.
The KFDA report...
KFDA to warn toad's grease and wood resin
The Daejeon regional KFDA warned the use of toad's grease and wood resin that are sold in the mobile peddlers on the streets for the treatment of skin diseases to protect consumers from its possible adverse reactions....
HIRA to hold international symposium on "evidence based medicine"
The Health Insurance Review Agency (www.hira.or.kr) announced to have an international symposium titled "The present and the future of evidence based medicine' at Lotte Hotel (located at Sogong dong, Seoul) on Sept. 1...
NHIC to provide useful informations through website.
The National Health Insurance Corporation (NHIC) provides 11 subjects of "Useful informations for medical institutions" covering the health information lectures, hospital acceptance times, the service times by differe...
Market influx of Plavix generic drugs.
Plavix (clopidogrel), an anti-thrombosis drug and a Sanofi-Synthelabo's top blockbuster, ended in its review term as of July 6, implying that its generic product influx into the markets would stage a fierce battle...
KFDA approved once-a-week dose of Enbrel
The KFDA approved once a week administering dose of Enbrel of Wyeth Korea Inc., a drug for the treatment of rheumatoid arthritis, 25mg of which previously approved for twice a week dose of 3 to 4 days interval.
Wy...
Obesity is a major cancer risk factor in Korea
The leading cause to the occurrence of cancer in Korea was attributed to obesity according to a study performed by Dr. Oh Sang-soo and associates of Ilsang Baik Hospital of Injae University Medical School and the NHIC...
279 new drugs newly to list in NHI price book.
279 new drugs seem to list in the NHI reimbursement schedule effective from August 1.
The NHI prices of 593 drugs that were found unfair trade practices such as discounts and allowances in the distribution process ...
LG Life Science to add adverse reactions to Calvan
LG Life Science announced that the adverse reactions such as hypotension, dyspepsia, abdominal pain and impotence should be added to the label of Calvan 50mg (bevantolol) as a result of its drug review by the KFDA.
...
Workshop for Bio Chip Researchers on July 26.
The KFDA plans to hold a workshop for the bio-chip researchers at the Korea Health and Welfare Human Resource Development Institute on July 26 in order to advance the bio-chip commercialization.
Bio-chip is compri...
